Evotec AG was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-roche-provides-initial-update-from-phase-iib-trial-in-alzheimers-disease-5293